Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 YAP and the drug resistance highway.

Literature DB >> 25711863

YAP and the drug resistance highway.

Alona Keren-Paz¹, Rafi Emmanuel¹, Yardena Samuels¹.

Abstract

Deciphering mechanisms of drug resistance is crucial to winning the battle against cancer. A new study points to an unexpected function of YAP in drug resistance and illuminates its potential role as a therapeutic target.

Entities: Chemical

Mesh：

Substances：

Year: 2015 PMID： 25711863 PMCID： PMC4881807 DOI： 10.1038/ng.3228

Source DB: PubMed Journal: Nat Genet ISSN： 1061-4036 Impact factor: 38.330

15 in total

Review 1. DNA-binding small molecules as inhibitors of transcription factors.

Authors: Chung-Hang Leung; Daniel Shiu-Hin Chan; Victor Pui-Yan Ma; Dik-Lung Ma
Journal: Med Res Rev Date: 2012-04-30 Impact factor: 12.944

Review 2. From genes to drugs: targeted strategies for melanoma.

Authors: Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal: Nat Rev Cancer Date: 2012-04-05 Impact factor: 60.716

3. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Authors: Luping Lin; Amit J Sabnis; Elton Chan; Victor Olivas; Lindsay Cade; Evangelos Pazarentzos; Saurabh Asthana; Dana Neel; Jenny Jiacheng Yan; Xinyuan Lu; Luu Pham; Mingxue M Wang; Niki Karachaliou; Maria Gonzalez Cao; Jose Luis Manzano; Jose Luis Ramirez; Jose Miguel Sanchez Torres; Fiamma Buttitta; Charles M Rudin; Eric A Collisson; Alain Algazi; Eric Robinson; Iman Osman; Eva Muñoz-Couselo; Javier Cortes; Dennie T Frederick; Zachary A Cooper; Martin McMahon; Antonio Marchetti; Rafael Rosell; Keith T Flaherty; Jennifer A Wargo; Trever G Bivona
Journal: Nat Genet Date: 2015-02-09 Impact factor: 38.330

4. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon.

Authors: Michael Overholtzer; Jianmin Zhang; Gromoslaw A Smolen; Beth Muir; Wenmei Li; Dennis C Sgroi; Chu-Xia Deng; Joan S Brugge; Daniel A Haber
Journal: Proc Natl Acad Sci U S A Date: 2006-08-07 Impact factor: 11.205

Review 5. Lessons from the cancer genome.

Authors: Levi A Garraway; Eric S Lander
Journal: Cell Date: 2013-03-28 Impact factor: 41.582

6. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.

Authors: John M Lamar; Patrick Stern; Hui Liu; Jeffrey W Schindler; Zhi-Gang Jiang; Richard O Hynes
Journal: Proc Natl Acad Sci U S A Date: 2012-08-13 Impact factor: 11.205

7. Quit your YAPing: a new target for cancer therapy.

Authors: Ben Z Stanger
Journal: Genes Dev Date: 2012-06-15 Impact factor: 11.361

8. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

Authors: Yi Liu-Chittenden; Bo Huang; Joong Sup Shim; Qian Chen; Se-Jin Lee; Robert A Anders; Jun O Liu; Duojia Pan
Journal: Genes Dev Date: 2012-06-07 Impact factor: 11.361

9. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Authors: Xiaodong Feng; Maria Sol Degese; Ramiro Iglesias-Bartolome; Jose P Vaque; Alfredo A Molinolo; Murilo Rodrigues; M Raza Zaidi; Bruce R Ksander; Glenn Merlino; Akrit Sodhi; Qianming Chen; J Silvio Gutkind
Journal: Cancer Cell Date: 2014-05-29 Impact factor: 31.743

Review 10. Targeting RAS signalling pathways in cancer therapy.

Authors: Julian Downward
Journal: Nat Rev Cancer Date: 2003-01 Impact factor: 60.716

22 in total

1. A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma.

Authors: Shumei Song; Min Xie; Ailing W Scott; Jiankang Jin; Lang Ma; Xiaochuan Dong; Heath D Skinner; Randy L Johnson; Sheng Ding; Jaffer A Ajani
Journal: Mol Cancer Ther Date: 2017-11-22 Impact factor: 6.261

Review 2. Unraveling the journey of cancer stem cells from origin to metastasis.

Authors: Rama Krishna Nimmakayala; Surinder K Batra; Moorthy P Ponnusamy
Journal: Biochim Biophys Acta Rev Cancer Date: 2018-11-09 Impact factor: 10.680

3. Downregulation of YAP inhibits proliferation, invasion and increases cisplatin sensitivity in human hepatocellular carcinoma cells.

Authors: Xiaoguang Wang; Bin Wu; Zhengxiang Zhong
Journal: Oncol Lett Date: 2018-05-04 Impact factor: 2.967

4. Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS).

Authors: Sojung Han; Ji Yeon Lim; Kyungjoo Cho; Hye Won Lee; Jun Yong Park; Simon Weonsang Ro; Kyung Sik Kim; Haeng Ran Seo; Do Young Kim
Journal: Cancers (Basel) Date: 2022-05-31 Impact factor: 6.575

Review 5. Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors: Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal: Signal Transduct Target Ther Date: 2020-10-07

Review 6. Cell density regulates cancer metastasis via the Hippo pathway.

Authors: Ghada M Sharif; Anton Wellstein
Journal: Future Oncol Date: 2015-11-12 Impact factor: 3.404

Review 7. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.

Authors: Markus Morkel; Pamela Riemer; Hendrik Bläker; Christine Sers
Journal: Oncotarget Date: 2015-08-28

8. PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.

Authors: Jai-Nien Tung; Po-Lin Lin; Yao-Chen Wang; De-Wei Wu; Chi-Yi Chen; Huei Lee
Journal: Oncotarget Date: 2017-12-08

Review 9. The Hippo signaling pathway provides novel anti-cancer drug targets.

Authors: June Sung Bae; Sun Mi Kim; Ho Lee
Journal: Oncotarget Date: 2017-02-28

10. Clinical implications of the Hippo-YAP pathway in multiple cancer contexts.

Authors: Han-Byul Kim; Seung-Jae Myung
Journal: BMB Rep Date: 2018-03 Impact factor: 4.778